Evaluation of new generation macrolides for the treatment and metaphylaxis of contagious bovine pleuropneumonia (CBPP) in cattle experimentally infected with Mycoplasma mycoides subspecies mycoides

Table 6 Experimental design and summary of study treatment groups

Group	Treatment	Dosage (mg/kg), Regimen, Route	CBPP Infection Kenya (VSRI)/Zambia (CVRI)	Number of Animals Kenya (VSRI)/Zambia (CVRI)^a	Intubation	Start of In-Contact Exposure Kenya (VSRI)/Zambia (CVRI)	Treatment Administration Kenya (VSRI)/ Zambia (CVRI)	Observation Period Kenya (VSRI)/Zambia (CVRI)
0	None	n/a	Intubation with Afadé/Caprivi strain	60/50	Day 0	8/11 days after intubation	n/a	49/49 days after intubation
1	Saline	6.0 mg/kg Once SC	In-contact with Group 0	15/13 (15)	n/a	8/11 days after intubation	41/38 days after start of in-contact exposure	92/73 days after treatment
2	Tulathromycin	2.5 mg/kg Once SC	In-contact with Group 0	15/13 (15)	n/a	8/11 days after intubation	41/38 days after start of in-contact exposure	92/73 days after treatment
3	Gamithromycin	6.0 mg/kg Once SC	In-contact with Group 0	15/13 (15)	n/a	8/11 days after intubation	41/38 days after start of in-contact exposure	92/73 days after treatment
4	Oxytetracycline	20.0 mg/kg Once IM	In-contact with Group 0	15/14 (15)	n/a	8/11 days after intubation	41/38 days after start of in-contact exposure	92/73 days after treatment
5	None	n/a	In-contact with Groups 1–4	20/18 (20)	n/a	32/28 days after treatment (Groups 1 to 4)	n/a	60/45 days after co-mingling

^aNumbers in brackets indicate the number of animals originally included into the study at CVRI: Seven animals from the combined group were withdrawn for welfare reasons unrelated to CBPP, before the start of the treatment phase and one sentinel was withdrawn before and one after co-mingling for welfare reasons unrelated to CBPP

ISSN: 1746-6148